Edward Fang

Edward Fang, MD, has over 15 years of experience in antibiotic drug development. He was most recently CMO of MicuRx Pharmaceuticals. Prior to MicuRx, he was CMO at Adenium Biotech. Earlier, he served as a director of clinical sciences at Trius, where he was the clinical lead for the development of Sivextro® (tedizolid). He was also previously an associate director at Cerexa, responsible for early-phase clinical studies of Teflaro® (ceftaroline). Dr. Fang received a BA from Stanford University and an MD from the UCLA School of Medicine, and he also completed a residency in internal medicine at UCLA.